Prevalence of mild behavioral impairment in patients with mild cognitive impairment

Gilda Kianimehr1, Farzad Fatehi2, Maryam Noroozian3

  • 1Department of Neuropsychiatry and Cognitive Neurology, Roozbeh Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, Iran.

Insights

Mild Behavioral Impairment (MBI) affects half of patients with Mild Cognitive Impairment (MCI). Common symptoms include impulse control issues, emotional dysregulation, and low motivation, signaling potential cognitive decline.

Area of Science:

  • Neuroscience
  • Geriatrics
  • Psychiatry

Background:

  • Neuropsychiatric symptoms (NPS) are increasingly recognized in dementia.
  • Mild Behavioral Impairment (MBI) and its subdomains require further investigation in Mild Cognitive Impairment (MCI).

Purpose of the Study:

  • To determine the prevalence of MBI and its subdomains in Iranian patients with MCI.
  • To explore the relationship between MBI, gender, and cognitive function in MCI patients.

Main Methods:

  • A cross-sectional study involving 96 MCI patients at a memory clinic.
  • Cognitive function assessed using the Persian Montreal Cognitive Assessment (MoCA).
  • MBI assessed via the Persian MBI Checklist (MBI-C) completed by patients or caregivers.

Main Results:

  • 50% of MCI patients (48/96) met the criteria for MBI.
  • No significant differences in MBI scores were found between genders or across different risk factors.
  • No significant difference in MoCA scores between MBI and non-MBI groups (p=0.59).
  • Most common NPS in MCI patients were impulse dyscontrol, emotional dysregulation, and decreased motivation.

Conclusions:

  • NPS, particularly MBI, are highly prevalent in MCI patients in Iran.
  • New-onset behavioral changes in older adults may indicate underlying cognitive impairment.
  • MBI symptoms like impulse dyscontrol, emotional dysregulation, and apathy are common in MCI.

Related Concept Videos

Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
241
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
923
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
429
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
266